**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 66481

**Manuscript Type:** MINIREVIEWS

**Radiofrequency ablation in the management of primary hepatic and biliary tumors**

Hendriquez R *et al*. RFA in Primary Hepatobiliary Tumors

Richard Hendriquez, Tara Keihanian, Jatinder Goyal, Rtika R Abraham, Rajnish Mishra, Mohit Girotra

**Richard Hendriquez,** Department of Internal Medicine, University of Central Florida, Orlando, FL 32816, United States

**Tara Keihanian,** Department of Gastroenterology and Hepatology, University of Miami, Miami, FL 33136, United States

**Jatinder Goyal,** Department of Gastroenterology and Hepatology, Wellspan Digestive Health - York Hospital, York, PA 17403, United States

**Rtika R Abraham,** Department of Endocrinology, Swedish Medical Center, Seattle, WA 98104, United States

**Rajnish Mishra, Mohit Girotra,** Digestive Health Institute, Section of Gastroenterology and Interventional Endoscopy, Swedish Medical Center, Seattle, WA 98104, United States

**Author contributions:** Henriquez R, Keihanian T and Goyal G performed data review, prepared and edited the manuscript; Abraham RR and Mishra R performed edited manuscript; Girotra M conceptualized and prepared, edited the manuscript and provided final approval; all authors wrote, read and approved the final manuscript.

**Corresponding author: Mohit Girotra, FACG, FACP, MD,** Digestive Health Institute, Section of Gastroenterology and Interventional Endoscopy, Swedish Medical Center, 1221 Madison Street, Ste 1220, Seattle, WA 98104, United States. girotra.mohit@gmail.com

**Received:** March 28, 2021

**Revised:** June 15, 2021

**Accepted:** December 7, 2021

**Published online:** January 15, 2022

**Abstract**

In the United States, 80%-90% of primary hepatic tumors are hepatocellular carcinomas and 10%-15% are cholangiocarcinomas (CCA), both with high mortality rate, particularly CCA, which portends a worse prognosis. Traditional management with surgery has good outcomes in appropriately selected patients; however, novel ablative treatment options have emerged, such as radiofrequency ablation (RFA), which can improve the prognosis of both hepatic and biliary tumors. RFA is aimed to generate an area of necrosis within the targeted tissue by applying thermal therapy *via* an electrode, with a goal to completely eradicate the tumor while preserving surrounding healthy tissue. Role of RFA in management of hepatic and biliary tumors forms the focus of our current mini-review article.

**Key Words:** Radiofrequency ablation; Radiofrequency ablation; Hepatic tumor; Biliary tumor; Cholangiocarcinoma; Hepatocellular carcinoma; Cholangiocarcinomas; Hepatocellular carcinomas

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Hendriquez R, Keihanian T, Goyal J, Abraham RR, Mishra R, Girotra M. Radiofrequency ablation in the management of primary hepatic and biliary tumors. *World J Gastrointest Oncol* 2022; 14(1): 203-215

**URL:** https://www.wjgnet.com/1948-5204/full/v14/i1/203.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v14.i1.203

**Core Tip:** Radiofrequency ablation (RFA) generates an area of necrosis within the targeted tissue by applying thermal therapy *via* an electrode, with a goal to completely eradicate the tumor while preserving surrounding healthy tissue. RFA can maintain biliary drainage by tumor ablation within the biliary ducts or occluded metallic stents, which improves survival and quality of life in unresectable cholangiocarcinomas patients. In hepatocellular carcinoma, RFA is used alone or in combination (with hepatectomy/transcatheter arterial chemoembolization) for ablation of tumors < 2 cm, and improves local tumor progression and recurrence-free survival, and considered by some to be comparative to hepatectomy.

**INTRODUCTION**

Most primary hepatic tumors are found to be either Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCA). Specifically, within the United States, 80%-90% of these tumors are found to be HCCs, and the remaining 10%-15% being CCAs[1-9]. These hepatic tumors have a high mortality rate, particularly CCA, which portends a worse prognosis[7,10-14]. Traditionally, surgical resection has been shown to have good outcomes in appropriately selected patients. However, with the advent of novel ablative treatment options such as radiofrequency ablation (RFA), the prognosis of both hepatic and biliary tumors can be improved[12,15,16].

Radiofrequency ablation (RFA) is aimed to generate an area of necrosis within the targeted tissue by applying thermal therapy *via* an electrode[17-20], with a goal to eradicate the tumor while preserving surrounding healthy tissue[12,21,22]. Thermal ablation has been used for management of a wide range of lesions, from renal tumors to uterine fibroids. However, more data is emerging in its role as a curative or palliative option in those with primary and secondary hepatobiliary malignancies[11,18-20]. In this mini-review article, we discuss the role of RFA in patients with primaryhepatic and biliary tumors.

**RFA TECHNIQUE AND PROCEDURE**

RFA utilizes electrodes to provide an alternating current, causing the ions to reverberate rapidly, thereby increasing tissue temperature[8,16,23-26]. This thermal energy induces coagulative necrosis and subsequent death of the malignant cells. RFA can be accomplished through multiple approaches, including surgical, percutaneous, and more recently, endoscopic modality[19,27,28]. Several studies have explored the safety, efficacy and feasibility of RFA for loco-regional control of tumor growth. To facilitate this, a specialized catheter named Endo Luminal RadiofrequencyAblation (ELRA) was developed (STARmed, Goyang, Korea), which is a 7-Fr bipolar catheter with a 1750 mm length, with an automatic temperature probe, allowing the user to avoid excessive heating and collateral damage to surrounding healthy tissue, thus decreasing the rates of procedure-related adverse events[29-32]. Four different exposure lengths are available (11, 18, 22 and 33 mm) to allow RFA of strictures of varying lengths, with recommended power setting of 7-10 W and target temperature of 80 °C for up to 2 min. A similar Habib EndoHPB catheter (Boston Scientific, Marlborough, MA, United States) is an 1800 mm long 8-Fr device with two distal tip electrodes placed 8 mm apart, to achieve biliary RFA. Novel devices have been developed to achieve the same *via* endoscopic ultrasound (EUS) approach. For example, the Habib endoscopic ultrasound (EUS) RFA device is a 1-Fr wire monopolar electrode inserted inside a standard EUS fine-needle aspiration (FNA) needle that can achieve coagulation of specific target tissue[12,21,33,34]. During endoscopic retrograde cholangiography (ERCP), after biliary cannulation a guidewire is passed through the strictured segment of bile duct, over which the RFA catheter is advanced and electrodes are positioned under fluoroscopic guidance to achieve ablation over bursts of 60 s. For longer strictures, stepwise ablation is performed to cover the entire length, or alternately catheter with varying exposure length can be utilized, if available. This modality can also be used to treat tumor/tissue ingrowth within metallic stents placed for cholangiocarcinoma (Figure 1). For strictures involving the hilum, ablation of both right and left hepatic ducts is performed after placement of two bilateral guidewires. After improvement of stricture, upstream debris removal is performed, followed by cholangiogram to assess for complications including bile leak, prior to stent placement.

**RFA IN CCC**

CCA represents approximately 2%-3% of malignancies arising from the gastrointestinal (GI) system, but is second most common primary liver tumor[7,34,35]. Specifically, these malignancies arise from the cells that line the biliary tree, and categorized as extra-hepatic or intra-hepatic, depending on their extent of ductal infiltration and location in relation to the cystic duct insertion; as most famously reported using the Bismuth-Corlette system[13,34]. Supplementary classifications of CCAs have been proposed, which in addition to tumor extent within the biliary system also take into account the size of the tumor, vascular (hepatic artery/portal vein) and lymph node involvement, distant metastases, and estimated post-resection hepatic volume[36], which have advantage over Bismuth-Corlette system which does not provide information on vascular encasement or metastatic disease, includes only peri-hilar CCA but not intrahepatic CCA, and does not necessarily determine local resectability, and hence of limited prognostic value. In fact, there is emerging evidence that although resection of type IV CCA is technically demanding with high morbidity, it can be performed with low mortality and offers better survival probability in selected patients[37].

When it comes to the treatment of CCAs, anatomical location and resectability play a crucial role. For those lesions that are considered resectable, surgical resection can be curable. Chemotherapy and radiation are typically utilized for unresectable lesions or can be used as neoadjuvant therapy for resectable tumors. For those tumors that cause obstruction, biliary drainage is usually the mainstay therapy with stent placement[29,32,38]. At present, extra-hepatic CCA is considered the condition most effectively treated with biliary RFA. Performance of RFA for intrahepatic CCA is challenging, and can be achieved *via* ERCP or EUS or percutaneous approach. RFA has also been employed to prolong the patency of stents in malignant obstructive tumors[27,38,39]. Typically the deployment of a self-expandable metallic stent (SEMS) is the mainstay palliative therapy in these patients. By prolonging the patency of stents, it improves survival and quality of life in patients with unresectable CCA.

Multiple studies have appraised the efficacy of RFA in the treatment of CCA and stent patency[33,40,41]. Cui and colleagues evaluated the effect of RFA on stent patency in malignant biliary obstruction, and while there was no significant difference in the overall survival, patency time was significantly increased in the RFA group at 7.6 mo when compared to 4.3 mo in the stent without RFA group. Another retrospective study by Li *et al*[29] determined hat stent patency was prolonged in those patients who underwent RFA plus stenting compared to stenting alone (81% *vs* 35%) with a *P* < 0.05. Furthermore, a meta-analysis by Sofi and colleagues, which included eight observational studies and one randomized controlled trial of RFA in malignant biliary obstruction showed not only a significantly prolonged stent patency in the RFA group when compared to the control group, but also a significant increase in overall survival in the RFA group (*n* = 504; 95%CI: 1.145-1.7; *P <* 0.01)[18]. Yang *et al*[20] performed a randomized control trial on patients with unresectable distal CCA and perihilar CCA; one group received RFA plus stenting (*n* = 32) and the other group received stenting alone (*n* = 33). Compared to stenting alone, the RFA plus stent group had a statistically significant increase in both patency (6.8 mo; 95%CI: 3.6-8.2 *vs* 3.4 mo; 95%CI: 2.4-6.5) and overall survival (13.2 mo *vs* 8.3 mo)[20]. These results are in contrast to previous reports, like by Wu *et al*[32], which has shown efficacy of RFA for stent patency, but no survival benefit. A detailed summary is provided in Table 1. Few studies have also compared Photodynamic therapy (PDT) with RFA, mostly without any statistically significant difference in overall survival between the two treatment approaches[42]. However, one of the retrospective studies did show that RFA conferred a short-term advantage in decline in bilirubin[43,44].

To summarize, RFA is a successful strategy for loco-regional management of extra-hepatic CCA, management of malignant biliary obstruction, as well as blocked metallic stents. The performance of RFA is operator dependent, and not protocol based, and hence timing and interval of RFA remains unclear, as well as choice of stents (plastic *vs* metallic). For intra-hepatic CCA, the access using ERCP-RFA catheters can be challenging, and alternative approaches may include EUS-RFA or percutaneous RFA by Interventional Radiology. Alternatives to RFA include Photodynamic Therapy (PDT), Microwave Ablation (MWA) and Irreversible Electroporation Ablation (IRE), all of which are complex and expensive procedures, which require highly specialized equipment, have side effects (photosensitivity with PDT) and complication profile, and hence not commonly performed worldwide. IRE is a non-thermal ablation modality, the basic principle of which is to create irreversible pores in cellular bi-lipid membranes by subjecting them to series of high intensity electrical pulses for short duration of time, resulting in cell death due to apoptosis, especially used for tumors located close to porta-hepatis. On the other hand, in MWA, tumor tissue is destroyed by direct hyperthermic injury produced by electromagnetic waves emitted from non-insulated portions of antenna, resulting in larger volume of active heating resulting in shorter procedure times, higher tissue temperatures beyond the threshold of water vaporization and less susceptibility to the heat sink effect of blood flow. Detailed discussion regarding these modalities is beyond the scope of this mini-review manuscript.

**RFA IN HCC**

HCC is the most common primary liver cancer and has the third-highest cancer-related mortality worldwide, exceeding 700000 deaths per year[2,3,5,6,45-47]. There are different causes of HCC, which vary worldwide; in Africa, aflatoxin B1 and chronic Hepatitis B infection seem to account for the most incidence of HCC, whereas cases in North America, Japan, and Europe are related to alcoholism and Hepatitis C infection[2,3,5,6,45-47]. Currently, the curative management options for HCC include liver transplantation, hepatectomy, or ablative therapies. Most patients diagnosed with HCC are not surgical candidates due to the advanced tumor size, invasion, or presence of metastasis[1-4,48]. Most management algorithms worldwide employ a specific scoring system named Barcelona Clinic Liver Cancer guidelines[1-6,48-50], to aids clinicians in determining the most appropriate management modality. Patients with early-stage HCC without any vascular invasion are classified as BCLC-A, which are suitable candidates for resection, ablation, or transplantation. On the other end of the treatment spectrum, patients with extra-hepatic tumor spread or vascular invasion are classified as BCLC-C, and are best managed with systemic therapies such as Sorafenib[1-6,48-50].

With the introduction of the Milan criteria, an increase in liver transplantation has been witnessed, ushering in a new era of curative treatment for HCC[51,52]. However, transplantation is dependent on donor availability, and since there are a limited number of donors, only a finite number of patients can undergo successful treatment. More importantly, patients may spend long periods of time awaiting transplant, allowing cancer to progress, which may disqualify formerly eligible patients from transplantation. To avoid this clinical dilemma, ablative techniques such as RFA become important for the crucial role they can play in delaying the malignancy progression[24,53-56]. A distinct advantage of these ablation techniques is that they can be performed safely on suboptimal surgical candidates.

RFA is the most widely used thermal ablative procedure used in patients with HCC[49,54,57,58], the success of which is inversely related to tumor size. Complete remission is achieved in approximately 90%-92% in those with tumor size < 2 cm whereas remission rates decrease to 20%-40% in those ≥ 2 cm in size[59]. While theoretically, multipolar electrodes may expand the ablation zone of RFA, this has not panned out in clinical studies. Cartier *et al*[60] compared traditional monopolar electrode RFA with multipolar electrodes in patients with tumors > 2.5 cm, and found no difference in residual tumor or recurrence. RFA seems to be a safe treatment option with procedure-related mortality of approximately 0.2% and an overall complication rate of 2.2%[61,62]. A novel RFA technique being studied is the "no-touch RFA protocol," which involves inserting multiple electrodes within the tissue that surrounds the tumor[62], which avoids direct contact with the tumor, allowing thermal ablation to be conducted with decreased risk of tumor seeding by the probe.

Several studies have investigated the effectiveness of RFA in HCC (Table 2). Liao *et al*[63] randomized 96 patients into those undergoing wide margin (WM ≥ 10 mm) ablation (*n* = 48) and normal margin (NM: ≥ 5 but < 10 mm) ablation (*n* = 48), and followed for mean period of 38.3 ± 4.8 mos. When analyzed based on intention-to-treat strategy, the 3-year incidences of local tumor progression (LTP) (14.9% *vs* 30.2%), intrahepatic recurrence (IHR) (15.0% *vs* 32.7%), and recurrence-free survival (RFS) (31.7 ± 12.1 *vs* 24.0 ± 11.7 mo) for WM group were significantly improved compared to NM group[63]. Getting recurrence-free survival advantage with RFA is a major success, for which RFA is adopted widely worldwide for smaller HCC, especially in non-resectable candidates. In regards to the “no-touch RFA protocol," a multicenter retrospective study of HCC < 5 cm in diameter (*n* = 362) showed effectiveness of this approach over monopolar RFA in terms of recurrence rates[62,63], but no statistical difference in 5-year survival rates (monopolar 37.2% *vs* no-touch multipolar 46.4% *P =* 0.378). Some investigators have proposed that stereotactic body radiotherapy (SBRT) was more effective than RFA, which has been challenged in recent studies[64,65]. In 2018, Rajyaguru *et al*[64] compared the effectiveness of RFA (*n* = 3684) against SBRT (*n* = 296), and their analysis support superior survival with RFA for non-surgically managed patients with stage I or II HCC. Various studies have investigated predictive factors to achieve improved outcomes in HCC when utilizing RFA. In a recent meta-analysis by Giardini *et al*[61,65-68](34 studies; *n* = 11,216), alpha-fetoprotein (AFP) < 20 ng/mL, Child-Pugh class A and albumin-bilirubin index of 1 were noted to confer increased survival benefit. In addition, survival also increased in patients with single tumor < 2 cm in diameter and preserved hepatic function[61,69-71].

Several studies have also explored the comparative success rates of RFA *vs* hepatectomy in HCC. A meta-analysis by Xu *et al*[72]indicated that RFA and surgical hepatectomy had similar overall survival at 1 year (relative risk [RR], 1.39; 95% confidence interval [CI]: 0.36, 5.33; *P =* 0.63) and 3 years (RR, 1.40; 95%CI: 0.75, 2.62; *P =* 0.29), whereas RFA resulted in decreased overall survival compared with HR at 5 years (RR: 1.91; 95%CI: 1.32, 2.79; *P =* 0.001)[72]. However, closer analysis of subgroup data, results showed no difference in survival between the groups in tumors less than 2.0 cm in size[72]. The Surveillance, Epidemiology and End Results (SEER) database explored the same question further stratified by age[65], and noted that patients older than 65 years with tumors less than 2 cm had similar survival to their propensity-matched group age less than 65 years. Interestingly, those < 65 years and tumors >3.0 cm had an increased overall survival with hepatectomy compared to RFA. However, large-scale studies have not been able to incorporate the novel RFA techniques previously discussed compared to hepatectomy[59,73,74]. Further studies will need to be conducted to answer this question.

Several studies have explored the role of combination therapy with RFA. In a recent meta-analysis, the pooled results showed that the 1-, 3-, 5-year overall survival rate in the combined RFA+hepatectomy group were comparable with those in the hepatectomy alone group (OR = 0.77, 0.96, 0.88; *P =* 0.33, 0.88, 0.70, respectively). Similarly, there was no significant difference in 1-, 3-, 5-year disease free survival rate between the combined group and the surgical alone group (OR = 0.57, 0.83, 0.72; *P =* 0.17, 0.37, 0.32, respectively). These results indicated that the hepatectomy combined with RFA could reach a long-term survival outcome similar to curative surgical resection for multifocal HCC patients, and this approach may be a promising alternative for patients with marginal liver function or complicated tumor distribution[75]. But, RFA+hepatectomy is limited due to its increased rate of post-op complications such as liver failure and death. Transcatheter arterial chemoembolization (TACE) is another commonly used percutaneous non-ablative treatment for HCC[76], which when combined with RFA yields a feasible treatment strategy with promising outcomes. In study by Kim *et al*[77], 1 mo, 6 mo, and 1-year tumor responses of TACE-RFA were similar to those of RFA and better than those of TACE. A distinct advantage of this combination therapy may be in patients with tumors located close to major vessels, wherein TACE occludes the hepatic artery flow, allowing a larger area for RFA ablation. This strategy minimizes the “heat-sink” effect associated with RFA. Regardless, the TACE-RFA group showed longer hospital stay and more frequent patient discomfort requiring medication than TACE or RFA monotherapy groups (*P <* 0.001), as well as the frequency of overall complications after TACE-RFA was higher than TACE (*P =* 0.006) or RFA (*P =* 0.009)[52,74,76-78]. Finally, RFA is also being utilized in combination with Sorafenib for management of HCC. A recent meta-analysis (15 studies, 2227 patients) showed that compared to RFA-alone, the patients in RFA+Sorafenib had longer 1-, 2- and 3-year overall survival (*P <* 0.05), better overall efficacy (*P <* 0.0001), longer RFA interval (*P <* 0.001) and lower 2-year recurrence rate (*P =* 0.02). However, this came at the cost of higher adverse reactions compared to RFA-alone group, including hand-foot skin reactions (*P <* 0.001), diarrhea and constipation (*P <* 0.0001), hypertension (*P =* 0.009) and alopecia (*P <* 0.001)[79]. Therefore, cognizance of overall adverse events is necessary while choosing the most optimal strategy. Despite these limitations, overall improvements in technology under development show promising prospects in the treatment of HCC.

**ADVERSE EVENTS AND LIMITATIONS OF RFA**

Several adverse events have been associated with RFA, the most common being post-procedure mild abdominal pain following either endoscopic or percutaneous RFA approaches. There seems to be a higher incidence of bleeding with percutaneous RFA, whereas a higher association of pancreatitis with the endoscopic approach[59,80]. Other post-procedure complications, such as hemobilia and hepatic artery pseudoaneurysms, have been postulated to be due to thermal injury[38,81]. This can be avoided with the newer ELRA RF catheter, which has a temperature probe. Further complications have been listed in Tables 1 and 2.

RFA does have its limitations. The therapeutic efficacy of RFA is inversely associated with tumor size and location[59]. RFA needs direct contact with the tissue, which can pose a challenge to treat tumors in inaccessible sites. Furthermore, tumors in close proximity to large vessels pose interesting therapeutic challenges[10,18,22,41,82,83]. Tumors located near large portal and hepatic vein branches can result in a "heat-sink" effect, which results in the inability to reach maximal ablation temperatures, thereby causing incomplete cell death[84]. It is important to keep in mind that RFA cannot be used in pregnancy or patients with cardiac devices or coagulopathy[24,73,82,83,85].

**CONCLUSION**

RFA has been established as novel and safe minimally invasive management tool for HCC. While multiple studies optimizing these techniques have shown promising results in patients with CCA, the low incidence of these biliary tumors makes it challenging to coordinate high-powered RCTs comparing various techniques and treatment strategies. It is paramount that future studies are coordinated through collaboration between various institutions of excellence for the progress of this still novel technique.

**REFERENCES**

1 **Avolio AW**, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, Mazzaferro V, Tisone G, Romagnoli R, Caccamo L, Rossi M, Vitale A, Cucchetti A, Lupo L, Gruttadauria S, Nicolotti N, Burra P, Gasbarrini A, Agnes S; Donor-to-Recipient Italian Liver Transplant (D2R-ILTx) Study Group. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. *Am J Transplant* 2011; **11**: 2724-2736 [PMID: 21920017 DOI: 10.1111/j.1600-6143.2011.03732.x]

2 **Bosetti C**, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. *Hepatology* 2008; **48**: 137-145 [PMID: 18537177 DOI: 10.1002/hep.22312]

3 **Bruix J**, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. *Gut* 2014; **63**: 844-855 [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627]

4 **Bruix J**, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. *Hepatology* 2005; **42**: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]

5 **Bruix J**, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

6 **Forner A**, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245-1255 [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0]

7 **Green BL**, House MG. Nonsurgical Approaches to Treat Biliary Tract and Liver Tumors. *Surg Oncol Clin N Am* 2019; **28**: 573-586 [PMID: 31472906 DOI: 10.1016/j.soc.2019.06.013]

8 **Lencioni R**, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. *Radiology* 2005; **234**: 961-967 [PMID: 15665226 DOI: 10.1148/radiol.2343040350]

9 **Loriaud A**, Denys A, Seror O, Vietti Violi N, Digklia A, Duran R, Trillaud H, Hocquelet A. Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems. *Int J Hyperthermia* 2018; **34**: 1171-1178 [PMID: 29457510 DOI: 10.1080/02656736.2018.1440017]

10 **Buerlein RCD**, Wang AY. Endoscopic Retrograde Cholangiopancreatography-Guided Ablation for Cholangiocarcinoma. *Gastrointest Endosc Clin N Am* 2019; **29**: 351-367 [PMID: 30846158 DOI: 10.1016/j.giec.2018.11.006]

11 **Chahal P**, Baron TH. Endoscopic palliation of cholangiocarcinoma. *Curr Opin Gastroenterol* 2006; **22**: 551-560 [PMID: 16891889 DOI: 10.1097/01.mog.0000239872.12081.a4]

12 **Labib PL**, Davidson BR, Sharma RA, Pereira SP. Locoregional therapies in cholangiocarcinoma. *Hepat Oncol* 2017; **4**: 99-109 [PMID: 29367874 DOI: 10.2217/hep-2017-0014]

13 **Qureshi K**, Jesudoss R, Al-Osaimi AM. The treatment of cholangiocarcinoma: a hepatologist's perspective. *Curr Gastroenterol Rep* 2014; **16**: 412 [PMID: 25183579 DOI: 10.1007/s11894-014-0412-2]

14 **Razumilava N**, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. *Clin Gastroenterol Hepatol* 2013; **11**: 13-21.e1; quiz e3-4 [PMID: 22982100 DOI: 10.1016/j.cgh.2012.09.009]

15 **Nault JC**, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. *J Hepatol* 2018; **68**: 783-797 [PMID: 29031662 DOI: 10.1016/j.jhep.2017.10.004]

16 **Shiina S**, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. *Am J Gastroenterol* 2012; **107**: 569-77; quiz 578 [PMID: 22158026 DOI: 10.1038/ajg.2011.425]

17 **Lee EW**, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. *Radiology* 2010; **255**: 426-433 [PMID: 20413755 DOI: 10.1148/radiol.10090337]

18 **Sofi AA**, Khan MA, Das A, Sachdev M, Khuder S, Nawras A, Lee W. Radiofrequency ablation combined with biliary stent placement *vs* stent placement alone for malignant biliary strictures: a systematic review and meta-analysis. *Gastrointest Endosc* 2018; **87**: 944-951.e1 [PMID: 29108980 DOI: 10.1016/j.gie.2017.10.029]

19 **Steel AW**, Postgate AJ, Khorsandi S, Nicholls J, Jiao L, Vlavianos P, Habib N, Westaby D. Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. *Gastrointest Endosc* 2011; **73**: 149-153 [PMID: 21184881 DOI: 10.1016/j.gie.2010.09.031]

20 **Yang J**, Wang J, Zhou H, Zhou Y, Wang Y, Jin H, Lou Q, Zhang X. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. *Endoscopy* 2018; **50**: 751-760 [PMID: 29342492 DOI: 10.1055/s-0043-124870]

21 **Larghi A**, Rimbaș M, Tringali A, Boškoski I, Rizzatti G, Costamagna G. Endoscopic radiofrequency biliary ablation treatment: A comprehensive review. *Dig Endosc* 2019; **31**: 245-255 [PMID: 30444547 DOI: 10.1111/den.13298]

22 **Lee DH**, Lee JM. Recent Advances in the Image-Guided Tumor Ablation of Liver Malignancies: Radiofrequency Ablation with Multiple Electrodes, Real-Time Multimodality Fusion Imaging, and New Energy Sources. *Korean J Radiol* 2018; **19**: 545-559 [PMID: 29962861 DOI: 10.3348/kjr.2018.19.4.545]

23 **Kim YS**, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Gwak GY, Yoo BC. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. *J Hepatol* 2013; **58**: 89-97 [PMID: 23023009 DOI: 10.1016/j.jhep.2012.09.020]

24 **Livraghi T**, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? *Hepatology* 2008; **47**: 82-89 [PMID: 18008357 DOI: 10.1002/hep.21933]

25 **Tateishi R**, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. *Cancer* 2005; **103**: 1201-1209 [PMID: 15690326 DOI: 10.1002/cncr.20892]

26 **Yan K**, Chen MH, Yang W, Wang YB, Gao W, Hao CY, Xing BC, Huang XF. Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. *Eur J Radiol* 2008; **67**: 336-347 [PMID: 17765421 DOI: 10.1016/j.ejrad.2007.07.007]

27 **Dolak W**, Schreiber F, Schwaighofer H, Gschwantler M, Plieschnegger W, Ziachehabi A, Mayer A, Kramer L, Kopecky A, Schrutka-Kölbl C, Wolkersdörfer G, Madl C, Berr F, Trauner M, Püspök A; Austrian Biliary RFA Study Group. Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. *Surg Endosc* 2014; **28**: 854-860 [PMID: 24196547 DOI: 10.1007/s00464-013-3232-9]

28 **Wang F**, Li Q, Zhang X, Jiang G, Ge X, Yu H, Nie J, Ji G, Miao L. Endoscopic radiofrequency ablation for malignant biliary strictures. *Exp Ther Med* 2016; **11**: 2484-2488 [PMID: 27284336 DOI: 10.3892/etm.2016.3235]

29 **Li TF**, Huang GH, Li Z, Hao CF, Ren JZ, Duan XH, Zhang K, Chen C, Han XW, Jiao DC, Zhang MF, Wang YL. Percutaneous transhepatic cholangiography and intraductal radiofrequency ablation combined with biliary stent placement for malignant biliary obstruction. *J Vasc Interv Radiol* 2015; **26**: 715-721 [PMID: 25817458 DOI: 10.1016/j.jvir.2015.01.037]

30 **Sharaiha RZ**, Natov N, Glockenberg KS, Widmer J, Gaidhane M, Kahaleh M. Comparison of metal stenting with radiofrequency ablation *vs* stenting alone for treating malignant biliary strictures: is there an added benefit? *Dig Dis Sci* 2014; **59**: 3099-3102 [PMID: 25033929 DOI: 10.1007/s10620-014-3264-6]

31 **Wu TT**, Li HC, Li WM, Ao GK, Lin H, Zheng F, Song JY. Percutaneous Intraluminal Radiofrequency Ablation for Malignant Extrahepatic Biliary Obstruction: A Safe and Feasible Method. *Dig Dis Sci* 2015; **60**: 2158-2163 [PMID: 25648642 DOI: 10.1007/s10620-015-3547-6]

32 **Wu TT**, Li WM, Li HC, Ao GK, Zheng F, Lin H. Percutaneous Intraductal Radiofrequency Ablation for Extrahepatic Distal Cholangiocarcinoma: A Method for Prolonging Stent Patency and Achieving Better Functional Status and Quality of Life. *Cardiovasc Intervent Radiol* 2017; **40**: 260-269 [PMID: 27743089 DOI: 10.1007/s00270-016-1483-2]

33 **Cui W**, Fan W, Lu M, Zhang Y, Yao W, Li J, Wang Y. The safety and efficacy of percutaneous intraductal radiofrequency ablation in unresectable malignant biliary obstruction: A single-institution experience. *BMC Cancer* 2017; **17**: 288 [PMID: 28438130 DOI: 10.1186/s12885-017-3278-5]

34 **Shaib Y**, El-Serag HB. The epidemiology of cholangiocarcinoma. *Semin Liver Dis* 2004; **24**: 115-125 [PMID: 15192785 DOI: 10.1055/s-2004-828889]

35 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

36 **Deoliveira ML**, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, Clavien PA. New staging system and a registry for perihilar cholangiocarcinoma. *Hepatology* 2011; **53**: 1363-1371 [PMID: 21480336 DOI: 10.1002/hep.24227]

37 **Ebata T**, Mizuno T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. *Br J Surg* 2018; **105**: 829-838 [PMID: 28488733 DOI: 10.1002/bjs.10556]

38 **Tal AO**, Vermehren J, Friedrich-Rust M, Bojunga J, Sarrazin C, Zeuzem S, Trojan J, Albert JG. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. *World J Gastrointest Endosc* 2014; **6**: 13-19 [PMID: 24527176 DOI: 10.4253/wjge.v6.i1.13]

39 **Wang Y**, Cui W, Fan W, Zhang Y, Yao W, Huang K, Li J. Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma. *Oncotarget* 2016; **7**: 53911-53920 [PMID: 27322076 DOI: 10.18632/oncotarget.10116]

40 **Cui W**, Wang Y, Fan W, Lu M, Zhang Y, Yao W, Li J. Comparison of intraluminal radiofrequency ablation and stents *vs* stents alone in the management of malignant biliary obstruction. *Int J Hyperthermia* 2017; **33**: 853-861 [PMID: 28540797 DOI: 10.1080/02656736.2017.1309580]

41 **Lee YN**, Jeong S, Choi HJ, Cho JH, Cheon YK, Park SW, Kim YS, Lee DH, Moon JH. The safety of newly developed automatic temperature-controlled endobiliary radiofrequency ablation system for malignant biliary strictures: A prospective multicenter study. *J Gastroenterol Hepatol* 2019; **34**: 1454-1459 [PMID: 30861593 DOI: 10.1111/jgh.14657]

42 **Yang J**, Shen H, Jin H, Lou Q, Zhang X. Treatment of unresectable extrahepatic cholangiocarcinoma using hematoporphyrin photodynamic therapy: A prospective study. *Photodiagnosis Photodyn Ther* 2016; **16**: 110-118 [PMID: 27720942 DOI: 10.1016/j.pdpdt.2016.10.001]

43 **Patel J**, Rizk N, Kahaleh M. Role of photodynamic therapy and intraductal radiofrequency ablation in cholangiocarcinoma. *Best Pract Res Clin Gastroenterol* 2015; **29**: 309-318 [PMID: 25966430 DOI: 10.1016/j.bpg.2015.02.008]

44 **Schmidt A**, Bloechinger M, Weber A, Siveke J, von Delius S, Prinz C, Schmitt W, Schmid RM, Neu B. Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma. *United European Gastroenterol J* 2016; **4**: 570-579 [PMID: 27536367 DOI: 10.1177/2050640615621235]

45 **Ikenaga N**, Chijiiwa K, Otani K, Ohuchida J, Uchiyama S, Kondo K. Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. *J Gastrointest Surg* 2009; **13**: 492-497 [PMID: 19011945 DOI: 10.1007/s11605-008-0751-0]

46 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/nejm199603143341104]

47 **Murray KF**, Carithers RL Jr; AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. *Hepatology* 2005; **41**: 1407-1432 [PMID: 15880505 DOI: 10.1002/hep.20704]

48 **Arii S**, Teramoto K, Kawamura T, Okamoto H, Kaido T, Mori A, Imamura M. Characteristics of recurrent hepatocellular carcinoma in Japan and our surgical experience. *J Hepatobiliary Pancreat Surg* 2001; **8**: 397-403 [PMID: 11702247 DOI: 10.1007/s005340100000]

49 **Figueroa-Barojas P**, Bakhru MR, Habib NA, Ellen K, Millman J, Jamal-Kabani A, Gaidhane M, Kahaleh M. Safety and efficacy of radiofrequency ablation in the management of unresectable bile duct and pancreatic cancer: a novel palliation technique. *J Oncol* 2013; **2013**: 910897 [PMID: 23690775 DOI: 10.1155/2013/910897]

50 **Freeman RB**, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. *Am J Transplant* 2006; **6**: 1416-1421 [PMID: 16686765 DOI: 10.1111/j.1600-6143.2006.01321.x]

51 **Huang J**, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg* 2010; **252**: 903-912 [PMID: 21107100 DOI: 10.1097/SLA.0b013e3181efc656]

52 **Liu W**, Zheng Y, He W, Zou R, Qiu J, Shen J, Yang Z, Zhang Y, Wang C, Wang Y, Zuo D, Li B, Yuan Y. Microwave *vs* radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. *Aliment Pharmacol Ther* 2018; **48**: 671-681 [PMID: 30063081 DOI: 10.1111/apt.14929]

53 **DuBay DA**, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, Guba M, Cattral MS, McGilvray ID, Grant DR, Greig PD. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. *HPB (Oxford)* 2011; **13**: 24-32 [PMID: 21159100 DOI: 10.1111/j.1477-2574.2010.00228.x]

54 **Fisher RA**, Maluf D, Cotterell AH, Stravitz T, Wolfe L, Luketic V, Sterling R, Shiffman M, Posner M. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. *Clin Transplant* 2004; **18**: 502-512 [PMID: 15344951 DOI: 10.1111/j.1399-0012.2004.00196.x]

55 **Lu DS**, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. *Hepatology* 2005; **41**: 1130-1137 [PMID: 15841454 DOI: 10.1002/hep.20688]

56 **Toso C**, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, Mentha G, Combescure C. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. *Hepatology* 2012; **56**: 149-156 [PMID: 22271250 DOI: 10.1002/hep.25603]

57 **Fontana RJ**, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. *Liver Transpl* 2002; **8**: 1165-1174 [PMID: 12474157 DOI: 10.1053/jlts.2002.36394]

58 **Hansen PD**, Cassera MA, Wolf RF. Ablative technologies for hepatocellular, cholangiocarcinoma, and metastatic colorectal cancer of the liver. *Surg Oncol Clin N Am* 2015; **24**: 97-119 [PMID: 25444471 DOI: 10.1016/j.soc.2014.09.003]

59 **Jiang YQ**, Wang ZX, Deng YN, Yang Y, Wang GY, Chen GH. Efficacy of Hepatic Resection *vs* Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size. *Front Oncol* 2019; **9**: 113 [PMID: 30863723 DOI: 10.3389/fonc.2019.00113]

60 **Cartier V**, Boursier J, Lebigot J, Oberti F, Fouchard-Hubert I, Aubé C. Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar? *J Gastroenterol Hepatol* 2016; **31**: 654-660 [PMID: 26414644 DOI: 10.1111/jgh.13179]

61 **Casadei Gardini A**, Marisi G, Canale M, Foschi FG, Donati G, Ercolani G, Valgiusti M, Passardi A, Frassineti GL, Scarpi E. Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. *Onco Targets Ther* 2018; **11**: 6555-6567 [PMID: 30323628 DOI: 10.2147/ott.S170836]

62 **Hocquelet A**, Aubé C, Rode A, Cartier V, Sutter O, Manichon AF, Boursier J, N'kontchou G, Merle P, Blanc JF, Trillaud H, Seror O. Comparison of no-touch multi-bipolar *vs* monopolar radiofrequency ablation for small HCC. *J Hepatol* 2017; **66**: 67-74 [PMID: 27422750 DOI: 10.1016/j.jhep.2016.07.010]

63 **Liao M**, Zhong X, Zhang J, Liu Y, Zhu Z, Wu H, Zeng Y, Huang J. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis: A prospective randomized trial. *J Surg Oncol* 2017; **115**: 971-979 [PMID: 28334430 DOI: 10.1002/jso.24607]

64 **Rajyaguru DJ**, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, Truty MJ, Kurup AN, Go RS. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. *J Clin Oncol* 2018; **36**: 600-608 [PMID: 29328861 DOI: 10.1200/jco.2017.75.3228]

65 **Parikh ND**, Marshall VD, Green M, Lawrence TS, Razumilava N, Owen D, Singal AG, Feng M. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare. *J Med Imaging Radiat Oncol* 2018; **62**: 673-681 [PMID: 29877615 DOI: 10.1111/1754-9485.12754]

66 **Nicoli N**, Casaril A, Marchiori L, Mangiante G, Hasheminia AR. Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation. *J Hepatobiliary Pancreat Surg* 2001; **8**: 417-421 [PMID: 11702250 DOI: 10.1007/s005340100003]

67 **Pai M**, Spalding D, Jiao L, Habib N. Use of bipolar radiofrequency in parenchymal transection of the liver, pancreas and kidney. *Dig Surg* 2012; **29**: 43-47 [PMID: 22441619 DOI: 10.1159/000335732]

68 **Pulvirenti A**, Garbagnati F, Regalia E, Coppa J, Marchiano A, Romito R, Schiavo M, Fabbri A, Burgoa L, Mazzaferro V. Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation. *Transplant Proc* 2001; **33**: 1516-1517 [PMID: 11267402 DOI: 10.1016/s0041-1345(00)02577-x]

69 **Brillet PY**, Paradis V, Brancatelli G, Rangheard AS, Consigny Y, Plessier A, Durand F, Belghiti J, Sommacale D, Vilgrain V. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. *AJR Am J Roentgenol* 2006; **186**: S296-S305 [PMID: 16632691 DOI: 10.2214/ajr.04.1927]

70 **Chan AC**, Poon RT, Cheung TT, Chok KS, Chan SC, Fan ST, Lo CM. Survival analysis of re-resection *vs* radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. *World J Surg* 2012; **36**: 151-156 [PMID: 22030561 DOI: 10.1007/s00268-011-1323-0]

71 **Cho YK**, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. *Hepatology* 2009; **49**: 453-459 [PMID: 19065676 DOI: 10.1002/hep.22648]

72 **Xu XL**, Liu XD, Liang M, Luo BM. Radiofrequency Ablation *vs* Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis. *Radiology* 2018; **287**: 461-472 [PMID: 29135366 DOI: 10.1148/radiol.2017162756]

73 **Majumdar A**, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis. *Cochrane Database Syst Rev* 2017; **3**: CD011650 [PMID: 28351116 DOI: 10.1002/14651858.CD011650.pub2]

74 **Mohkam K**, Dumont PN, Manichon AF, Jouvet JC, Boussel L, Merle P, Ducerf C, Lesurtel M, Rode A, Mabrut JY. No-touch multibipolar radiofrequency ablation *vs* surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. *J Hepatol* 2018; **68**: 1172-1180 [PMID: 29410287 DOI: 10.1016/j.jhep.2018.01.014]

75 **Xu LL**, Zhang M, Yi PS, Zheng XB, Feng L, Lan C, Tang JW, Ren SS, Xu MQ. Hepatic resection combined with radiofrequency ablation *vs* hepatic resection alone for multifocal hepatocellular carcinomas: A meta-analysis. *J Huazhong Univ Sci Technolog Med Sci* 2017; **37**: 974-980 [PMID: 29270762 DOI: 10.1007/s11596-017-1836-3]

76 **Martin AN**, Wilkins LR, Das D, Johnston LE, Bauer TW, Adams RB, Zaydfudim VM. Efficacy of Radiofrequency Ablation *versus* Transarterial Chemoembolization for Patients with Solitary Hepatocellular Carcinoma ≤ 3 cm. *Am Surg* 2019; **85**: 150-155 [PMID: 30819290]

77 **Kim W**, Cho SK, Shin SW, Hyun D, Lee MW, Rhim H. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy. *Abdom Radiol (NY)* 2019; **44**: 2283-2292 [PMID: 30806742 DOI: 10.1007/s00261-019-01952-1]

78 **Mizandari M**, Pai M, Xi F, Valek V, Tomas A, Quaretti P, Golfieri R, Mosconi C, Guokun A, Kyriakides C, Dickinson R, Nicholls J, Habib N. Percutaneous intraductal radiofrequency ablation is a safe treatment for malignant biliary obstruction: feasibility and early results. *Cardiovasc Intervent Radiol* 2013; **36**: 814-819 [PMID: 23232859 DOI: 10.1007/s00270-012-0529-3]

79 **Jin M**, Yu Q, Liu Y, Xu W, Fu X, Ji B. Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis. *J Clin Transl Hepatol* 2021; **9**: 149-159 [PMID: 34007796 DOI: 10.14218/jcth.2020.00125]

80 **Germani G**, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. *J Hepatol* 2010; **52**: 380-388 [PMID: 20149473 DOI: 10.1016/j.jhep.2009.12.004]

81 **Laquière A**, Boustière C, Leblanc S, Penaranda G, Désilets E, Prat F. Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma. *Surg Endosc* 2016; **30**: 1242-1248 [PMID: 26162420 DOI: 10.1007/s00464-015-4322-7]

82 **Kang TW**, Lim HK, Cha DI. Percutaneous ablation for perivascular hepatocellular carcinoma: Refining the current status based on emerging evidence and future perspectives. *World J Gastroenterol* 2018; **24**: 5331-5337 [PMID: 30598578 DOI: 10.3748/wjg.v24.i47.5331]

83 **Lurje I**, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. *Int J Mol Sci* 2019; **20** [PMID: 30909504 DOI: 10.3390/ijms20061465]

84 **Weber JC**, Navarra G, Jiao LR, Nicholls JP, Jensen SL, Habib NA. New technique for liver resection using heat coagulative necrosis. *Ann Surg* 2002; **236**: 560-563 [PMID: 12409660 DOI: 10.1097/00000658-200211000-00004]

85 **Koda M**, Ueki M, Maeda Y, Mimura KI, Okamoto K, Matsunaga Y, Kawakami M, Hosho K, Murawaki Y. The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. *Hepatol Res* 2004; **29**: 18-23 [PMID: 15135342 DOI: 10.1016/j.hepres.2004.02.001]

86 **Sharaiha RZ**, Sethi A, Weaver KR, Gonda TA, Shah RJ, Fukami N, Kedia P, Kumta NA, Clavo CM, Saunders MD, Cerecedo-Rodriguez J, Barojas PF, Widmer JL, Gaidhane M, Brugge WR, Kahaleh M. Impact of Radiofrequency Ablation on Malignant Biliary Strictures: Results of a Collaborative Registry. *Dig Dis Sci* 2015; **60**: 2164-2169 [PMID: 25701319 DOI: 10.1007/s10620-015-3558-3]

87 **Strand DS**, Cosgrove ND, Patrie JT, Cox DG, Bauer TW, Adams RB, Mann JA, Sauer BG, Shami VM, Wang AY. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma. *Gastrointest Endosc* 2014; **80**: 794-804 [PMID: 24836747 DOI: 10.1016/j.gie.2014.02.1030]

88 **Alis H**, Sengoz C, Gonenc M, Kalayci MU, Kocatas A. Endobiliary radiofrequency ablation for malignant biliary obstruction. *Hepatobiliary Pancreat Dis Int* 2013; **12**: 423-427 [PMID: 23924501 DOI: 10.1016/s1499-3872(13)60066-1]

89 **Zhang L**, Wang N, Shen Q, Cheng W, Qian GJ. Therapeutic efficacy of percutaneous radiofrequency ablation *vs* microwave ablation for hepatocellular carcinoma. *PLoS One* 2013; **8**: e76119 [PMID: 24146824 DOI: 10.1371/journal.pone.0076119]

90 **Kalra N**, Kang M, Duseja AK, Bhatia A, Singh V, Dhiman RK, Rajwanshi A, Chawla YK, Khandelwal N. Comparison of radiofrequency ablation alone and in combination with percutaneous ethanol injection for management of hepatocellular carcinoma. *Indian J Med Res* 2017; **146**: S30-S37 [PMID: 29578192 DOI: 10.4103/ijmr.IJMR\_1812\_15]

91 **Abdelaziz AO**, Abdelmaksoud AH, Nabeel MM, Shousha HI, Cordie AA, Mahmoud ShH, Medhat E, Omran D, Elbaz TM. Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma *Asian Pac J Cancer Prev* 2017; **18**: 189-194 [PMID: 28240516 DOI: 10.22034/apjcp.2017.18.1.189]

92 **Györi GP**, Felsenreich DM, Silberhumer GR, Soliman T, Berlakovich GA. Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation. *Eur Surg* 2017; **49**: 236-243 [PMID: 29104589 DOI: 10.1007/s10353-017-0487-8]

93 **Hao Y**, Numata K, Ishii T, Fukuda H, Maeda S, Nakano M, Tanaka K. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma. *World J Gastroenterol* 2017; **23**: 3111-3121 [PMID: 28533668 DOI: 10.3748/wjg.v23.i17.3111]

94 **Santambrogio R**, Barabino M, Bruno S, Mariani N, Maroni N, Bertolini E, Franceschelli G, Opocher E. Surgical Resection *vs* Ablative Therapies Through a Laparoscopic Approach for Hepatocellular Carcinoma: a Comparative Study. *J Gastrointest Surg* 2018; **22**: 650-660 [PMID: 29235004 DOI: 10.1007/s11605-017-3648-y]

**Footnotes**

**Conflict-of-interest statement:** The authors have no disclosures or conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American Gastroenterological Association; American College of Gastroenterology; American Society for Gastrointestinal Endoscopy.

**Peer-review started:** March 28, 2021

**First decision:** June 7, 2021

**Article in press:** December 7, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Lang SA **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Figure Legends**



**Figure 1 Cholangiocarcinoma stricture and radiofrequency ablation.** A: Tumor ingrowth into uncovered metallic stent (placed for distal cholangiocarcinoma), allowing passage of guidewire but no other equipment; B: Treated with Habib radiofrequency ablation probe, to achieve patency of stent, which allowed successful biliary drainage.

**Table 1 Utilization of radiofrequency ablation for cholangiocarcinoma**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Technique** | **Ref.** | **Number of Patients** | **Location** | **Stent type** | **Mean number of sessions** | **Patency of stent (d, median)** | **Stent occlusion** | **Survival** | **Adverse events** |
|  | Mizandari *et al*[[78](#_ENREF_78)], 2013 | 39 | CCA (17); Bismuth I (5); II (1); IIIa (4); IV (7)-Panc CA (11), GB CA (4), HCC (1), Ampullary CA (1), Metastatic CA (5) | SEMS (all) | 1 | 84.5 | 1 | 3 mo (median) | Abdominal pain (15) |
|  | Wu *et al*[32], 2017 | 71 [RFA and stenting = 35, stenting alone = 36] | Extra-hepatic distal CCA | Covered SEMS (7); uncovered SEMS (28) | 1 | Uncovered SEMS (241); covered SEMS (212) | - | Uncovered SEMS (245 d, median); covered SEMS (278 d, median) | Abdominal pain (27) |
| Percutaneous | Li *et al*[29], 2015 | 26  [RFA and stenting = 12, stenting alone = 14] | Hilar (2), middle and distal CBD (7), Panc CA (2), ampullary CA (1) | SEMS (all) | 1 | RFA group (0), control group (3) | RFA group 100%; control group 85% at 90 d | - | Cholangitis (3) |
|  | Wu *et al*[31], 2015 | 47 | Hilar (7), distal CBD (16); ampullary CA (8); Panc CA (6); GB CA (4); HCC (2); Metastatic disease (4) | SEMS | 1.38 | 149 | 11 | 6 mo | Abdominal pain (21), intra-abdominal hemorrhage (1) |
|  | Wang *et al*[28], 2016 | 9 | Bismuth IIIa (1); IIIb (1); IV (7) | SEMS | 1 (only 1 patient had 2 sessions) | 100 | - | 5.3 mo | Abdominal pain (3); Cholangitis (4) |
|  | Wang *et al*[39], 2016 | 12 | Bismuth I (5); IIIa (1); IV (3); Gastric CA (1); HCC(1); Congenital Choledochal cyst (1) | Plastic (7); SEMs (4) | 1 | 125 | - | 7.7 mo (median) | Fever (2), pancreatitis (1) |
|  | Laquière *et al*[81], 2016 | 12 | Bismuth I (4); II (3); III (2); IV (3) | Plastic and Metallic (does not quantify) | 1.63 | - | 4 | 12.3 mo | Sepsis (1), early stent migration (1), late stent migration (1), cholangitis (1) |
| Endoscopic | Sharaiha *et al*[86], 2015 | 69 | Hilar (23); proximal CBD (7); distal CBD (7); Bismuth I (4); Bismuth III (2); Bismuth IV (5); Panc CA (19); GB CA (2); Gastric CA (1), Metastasis disease (3) | Metallic (49); Plastic (20) | 1.3 | 95% at 30 d | 3 | 17.7 ± 15.4 mo | Pancreatitis (1); Cholecystitis (2); Haemobilia (1); abdominal pain (3) |
|  | Strand *et al*[87], 2014 | 16 | Intrahepatic/proximal (1); Hilar (13); Extrahepatic/distal (2) | Plastic (3); fully covered SEMS (3); uncovered SEMS (11) | 1.19 | - | 0.06 | 9.6 mo | Stent migration (0.02); cholangitis (0.13); hepatic abscess (0.02); need for percutaneous drainage (0.01); severe abdominal pain (0.02) (occurrence per month) |
|  | Sharaiha *et al*[30], 2014 | 64 | CCA (18); Panc CA (8) | Covered SEMS (8); uncovered SEMS (7); Plastic (11) | 1 | 100% at 90 d | 0 | 5.9 mo | Abdominal pain (3); Pancreatitis (1); Cholecystitis (1) |
|  | Alis *et al*[88], 2013 | 10 | Bismuth I (4); Distal CBD (6) | SEMS (all) | 1 | 270 | 0 | - | Pancreatitis (2) |
|  | Figueroa Barojas *et al*[49], 2013 | 20 | CCA (11); Panc CA (7); Gastric Ca (1), IPMN with high grade dysplasia (1) | Plastic (6); covered SEMS (13); uncovered SEMS (1) | 1.25 | 100% at 30 d | 0 | - | Abdominal pain (5); Pancreatitis (1); Cholecystitis (1) |
|  | Steel *et al* [19], 2011 | 21 | CCA (6); Panc CA (16) | Uncovered SEMS (all) | 2 | 114 (median stent patency at 9- d) | 4 | - | Pancreatitis (1); cholecystitis (2), obstructive jaundice/death (1) |
| Percutaneous and endoscopic | Dolak *et al*[27], 2014 | 58 | Bismuth I (5); II (1); III (6); IV (33); distal CBD (5);Panc CA (4), central HCC,mCRC(3) | Plastic (19); SEMS (35); no stent (4) | 1.44 | 170 (Metallic stent = 218, Plastic stent = 115) | - | 10.9 mo (median) | Cholangitis (5); hemobilia (2); sepsis (2); hepatic coma (1); hepatic infarction (1) |

CBD: Common bile duct; CCA: Cholangiocarcinoma; GA Ca: Gallbladder cancer; Panc CA: Pancreatic cancer; mCRC: Metastatic colorectal cancer; SEMS: Self-expanding metallic stent.

**Table 2 Utilization of Radiofrequency ablation for hepatocellular carcinoma**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type** | **N** | **Technique** | **Survival** | **Recurrence** | **Adverse Events** | **Outcome** |
| Zhang *et al*[89], 2013 | Retrospective | 155 | RFA (78- 93 sessions) and MWA (77-91 sessions) | 1-, 3-, and 5-year overall survival rates: RFA: 91.0%, 64.1% and 41.3%; MWA: 92.2%, 51.7%, and 38.5% | RFA: 11/93 (11.8%) and MWA: 11/105 (10.5%) | RFA group: persistent jaundice (n  =  1) and biliary fistula (n  =  1). MWA group: hemothorax and intrahepatic hematoma (n  =  1) and peritoneal hemorrhage (n  =  1) | No significant differences LTP, DR, and overall survival |
| Karla *et al*[90], 2017 | Prospective | 50 | RFA alone (25) and RFA + alcohol ablation (25) | RFA alone 84%; RFA + alcohol (80%) (at 6 month) | Local recurrence (11); Distant intrahepatic tumor recurrence (4) | Hemoperitoneum (1) | Combined use of RFA and alcohol did not improve the local tumor control and survival |
| Abdelaziz *et al*[91], 2017 | Retrospective | 67 | TACE-RFA (22) and TACE-MWA (45) | Survival at 1, 2 and 3 years: TACE-MWA: 83.3%, 64.7%, 64.7%; TACE-RFA: 73.1%, 40.6% and 16.2% (*P* *=* 0.08) | TACE-RFA: 4 (18.2%); TACE-MWA: 8 (17.8%) | TACE-RFA: bone metastases 1 (4.5%), Ascites 3 (13.6%), variceal bleeding 5 (22.7%); TACE-MWA: portal vein thrombosis: 1 (2.2%), ascites 6 (13.3%), variceal bleeding: 4 (8.9%) | No significant difference in overall survival was observed |
| Gyori *et al*[92], 2017 | Retrospective | 150 | 54% (*n =* 81) received TACE-based LRT, 26% (*n =* 39) PEI/RFA regimen, and 17% (*n =* 26) had no treatment while on the waiting list | No difference in overall survival after liver transplantation when comparing TACE- and RFA-based regimens |  |  | TACE- and RFA-based regimens showed equal outcomes in terms of transplantation rate, tumor response, and post-transplant survival. Lower survival in recipients of Multimodality LRT |
| Hao *et al*[93], 2017 | Retrospective | 237 | 50 pathologically early HCCs, 187 typical HCCs |  | LTP observed in 1 Early HCC (2%); 46 Typical HCC (24.6%) | Fever, abdominal pain and elevated liver enzyme levels | Rate of LTP for early HCCs after RFA was significantly lower than typical HCCs |
| Liao *et al*[63], 2017 | Prospective randomized | 96 | 48 patients wide margin (WM) ablation (≥ 10 mm) and 48 normal margin (NM) ablation (≥ 5 mm but < 10 mm ) | The 1-, 2-, and 3-year survival rates: WM: 95.8%, 91.6%, and 74.6%; NM: 95.8%, 78.4%, and 60.2% | 3-year LTP: WM: 14.9%; NM: 30.2% Intrahepatic recurrence (IHR): WM: 15.0% NM: 32.7% | Perihepatic bile collection (1); intrahepatic hemorrhage(1); fever(1); liver infarction (1); thermal skin injury (1); pleural effusion (1) | WM-RFA may reduce the incidence of tumor recurrence among cirrhotic patients with small HCCs |
| Rajyaguru *et al*[64], 2018 | Observational | 3980 | RFA (3,684) and SBRT (296) | 5 yr overall survival: RFA: 29.8% (95%CI: 24.5-35.3%); SBRT: 19.3% (95%CI: 13.5-25.9%) |  |  | Treatment with RFA yields superior survival compared with SBRT for nonsurgically managed patients with stage I or II HCC |
| Parick *et al*[65], 2018 | Retrospective cohort | 440 | RFA (408) and SBRT (32) | RFA patients had better overall survival (*P* < 0.001) |  |  | SBRT (HR 1.80; 95%CI: 1.15-2.82) associated with worse survival |
| Santambrogio *et al*[94], 2018 | Prospective controlled | 264 | Laparoscopic hepatic resection (LHR = 59) *vs* laparoscopic ablation therapy (LAT = 205) | Survival rates LHR at 1, 3, and 5 years were 93, 82, and 56%. In LAT = 91%, 62%, and 40% | LHR = 24/59 (41%); LAT = 135/205 (66%) |  | LAT found to be adequate alternative |

OLT: Orthotopic liver transplantation; LRT: Locoregional treatment; LTP: Local Tumor Progression; TACE: Transarterial chemoembolization; PEI: Percutaneous ethanol injection; SBRT: Stereotactic body radiotherapy; MWA: Microwave ablation; DR: Distant recurrence.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**